MasterCard Inc vs uniQure N.V. Ordinary Shares — how do they compare? MasterCard Inc trades at $608 (market cap $528.44B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: MasterCard Inc is far larger — about 364.4× uniQure N.V. Ordinary Shares's market cap, and MasterCard Inc pays a 0.58% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MA | QURE | |
|---|---|---|
Market Cap | $528.44B | $1.45B |
Volume | 3,240,513 | 3,323,243 |
Sector | Financials | Health |
52-Week High | $604.80 | $70.59 |
52-Week Low | $471.55 | $9.03 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $541.48B | $707.46M |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $604.80, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining impressive profit margins above 45%. Recent earnings beats and institutional buying activity support the positive outlook, while the company continues expanding digital payment infrastructure globally.
Mastercard presents a compelling growth opportunity with 80% analyst buy ratings and a $668.67 consensus price target. Key risks include payment industry disruption from stablecoins and AI-driven competitors. The stock's premium valuation (P/E 33.27) requires sustained execution, but strong cash flow generation and strategic positioning support long-term upside potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →